On Jun. 15, 2020, Eli Lilly announced that the first patient has been enrolled in a Phase 3 randomized, double-blind, placeboﾖcontrolled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults with COVID-19.

Baricitinib, marketed as OLUMIANTﾮ, is approved in 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis (RA).